A Study of Single Ascending Doses of STAR-101 in Healthy Participants

NCT04081597 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-02-13

No results posted yet for this study

Summary

The study will include a single ascending dose approach to evaluate the safety, tolerability, and pharmacokinetic properties of STAR-101 after a single oral administration in healthy participants

Conditions

  • Healthy Volunteers

Interventions

DRUG

Star-101

Administered orally

DRUG

Placebo

Administered orally

Sponsors & Collaborators

  • Acanthas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Acanthas Pharma · Acanthas Pharma

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-29
Primary Completion
2020-03-31
Completion
2020-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04081597 on ClinicalTrials.gov